The evolution and promise of gene therapies
Dr David Baram from gene therapy company EmendoBio provides a snapshot of the history of therapeutic genetic engineering.
List view / Grid view
Articles
Women in STEM with Dr Jo Brewer
Come and join us for our monthly series highlighting Women in STEM. We are excited to present the latest edition for June, featuring an exclusive interview with Dr Jo Brewer, Chief Scientific Officer at Adaptimmune. With a remarkable 15-years of experience in cell therapy, Jo's passion for cells has been…
The role of CRISPR in microbiome engineering breakthroughs
Dr Jakob Krause Habber and Dr Richard Fox will explore the applications of CRISPR in microbiome engineering and how it can be used to overcome the bottleneck of human microbiome research.
Drug Target Review Imaging eBook
In this eBook, explore how cutting-edge imaging modalities can elevate your biomedical research.
Drug Target Review Screening eBook 2023
27 June 2023 | By
In this eBook, uncover the transformative potential of AI/ML in single-cell technologies and gain insights into disease progression.
Drug Target Review Cell and Gene Therapy eBook 2023
Download your FREE ebook, featuring articles about cancer therapies, immune system breakthroughs, therapeutic genetic engineering, and advancements in gene editing.
Drug Target Review – Issue 2 2023
A new Drug Target Review issue is now ready to download! This issue features articles on cell and gene therapy, imaging and screening.
The genetic modifier approach: identifying the right target for rare diseases
In this article, Dr Vincent Blomen, Senior Director of Target Discovery at Scenic Biotech, takes us through the realm of rare diseases. In the case of most of these diseases, a singular genetic anomaly often reigns supreme, yet its impact on patients can be vastly divergent. Enter modifier genes, the…
RNA processing in health and disease: challenges and opportunities of the field
In this interview, Sam Hasson, Senior Director at Rgenta Therapeutics, shares his journey in drug discovery, from graduate school to industry, and his current work developing small molecule therapeutics to target RNA processing. He discusses the challenges and opportunities in the field of RNA-centric drug discovery and highlights the potential…
ebook: Breaking Barriers in Cell Engineering
Download this FREE ebook now and explore single-cell analysis, unlocking the secrets of therapeutic efficacy and safety. Immerse yourself in exclusive content, including cutting-edge cell line development articles and riveting interviews with industry experts. Don't miss your chance to discover the future of cellular therapies – start your journey today!
Game-changing pan-TEAD inhibitor for solid tumours
Insilico Medicine has announced the nomination of ISM6331 as a potential best-in-class pan-TEAD inhibitor for the treatment of advanced solid tumours.
Neoantigen-directed cancer treatment
This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, explores research on T-cell therapy for cancer, which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.
Chemotherapy-free treatment for patients with blood cancer
Dr Andy Souers highlights the unwavering commitment to finding an enhanced therapeutic approach that eliminates the need for chemotherapy in blood cancer treatment. This transformative discovery represents a significant leap forward in the way we combat this complex disease, offering new hope to countless patients worldwide.
Targeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering
In this article Dr Raymond Winquist, Oncology Fellow at Alkermes, covers the longstanding research challenges associated with cytokines: IL-12 and IL-18, and their untapped potential in immunotherapy and immuno-oncology.
Breakthrough drug candidates and cancer treatment innovations
In this exclusive interview with Dr Paul Moore, Chief Scientific Officer from Zymeworks, we explore the impressive responses of Zymeworks' antibody-drug conjugate ZW191 in FRα-low expressing models, indicating its efficacy in treating various oncology indications.
